Mauricette Michallet
Overview
Explore the profile of Mauricette Michallet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
255
Citations
5776
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fervers B, Perol O, Lasset C, Moumjid N, Vidican P, Saintigny P, et al.
Cancer Prev Res (Phila)
. 2024 Apr;
17(4):133-140.
PMID: 38562091
This article describes some of the key prevention services in the Leon Berard Comprehensive Cancer Center (CLB) Lyon, France, which are based on clinical prevention services, outreach activities, and collaboration...
2.
Michallet M, Sobh M, Deloire A, Revesz D, Chelgoum Y, El-Hamri M, et al.
Transfus Apher Sci
. 2024 Feb;
63(3):103899.
PMID: 38402067
Background & Objectives: The primary objective of this observational study was to perform an exhaustive description concerning patients receiving extracorporeal photopheresis (ECP) as second line treatment after steroid resistance for...
3.
Philippe M, Guitton J, Goutelle S, Thoma Y, Favier B, Chtiba N, et al.
Ther Drug Monit
. 2023 Nov;
46(1):127-131.
PMID: 37941111
Background: Venetoclax (VNX)-based regimens have demonstrated significantly favorable outcomes in patients with acute myeloid leukemia (AML) and are now becoming the standard treatment. Tyrosine kinase inhibitors are administered at a...
4.
Belhabri A, Heiblig M, Morisset S, Vila L, Santana C, Nicolas-Virelizier E, et al.
Cancer Med
. 2023 Aug;
12(16):16929-16944.
PMID: 37548369
Background: t-AML occurs after a primary malignancy treatment and retains a poor prognosis. Aims: To determine the impact of primary malignancies, therapeutic strategies, and prognostic factors on clinical outcomes of...
5.
Baron F, Ruggeri A, Peczynski C, Labopin M, Bourhis J, Michallet M, et al.
Bone Marrow Transplant
. 2023 May;
58(8):936-941.
PMID: 37165084
Graft failure has remained a limitation of umbilical cord blood transplantation (CBT). Here, we assessed the outcomes of patients who experienced graft failure after CBT. Inclusion criteria were patients (age ...
6.
Laloi L, Billotey N, Dumas P, Paul F, Villate A, Simand C, et al.
Cancer Med
. 2022 Dec;
12(6):7175-7181.
PMID: 36482507
Background: Recently, the combination of venetoclax plus a hypomethylating agent (HMA; azacitidine ordecitabine) or low-dose cytarabine (LDAC) showed promise in Phase III trials in previously untreated AML. In France at...
7.
Rafii H, Ruggeri A, Kenzey C, Sanz J, Peffault De La Tour R, Esquirol A, et al.
Blood Adv
. 2022 Nov;
7(10):1976-1986.
PMID: 36350759
Subsequent neoplasms (SNs) compromise long-term survivors after hematopoietic cell transplantation. We performed a retrospective analysis of SNs in 10 358 recipients of umbilical cord blood transplantation (UCBT) from 1988 to...
8.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, et al.
Clin Cancer Res
. 2022 Oct;
28(23):5211-5220.
PMID: 36201165
Purpose: To provide insights into the diagnosis and management of therapy-related myeloid neoplasms (t-MN) following PARP inhibitors (PARPi). Experimental Design: In a French cancer center, we identified and described the...
9.
Le Meur G, Plesa A, Larcher M, Fossard G, Barraco F, Loron S, et al.
Transplant Cell Ther
. 2022 Sep;
29(1):38.e1-38.e9.
PMID: 36108977
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) after conditioning with a sequential association of fludarabine, amsacrine, and cytosine arabinoside (FLAMSA) followed by a reduced-intensity conditioning regimen has emerged for patients with...
10.
Michallet M, El Cheikh J, Herbrecht R, Yakoub-Agha I, Caillot D, Gangneux J
BMC Infect Dis
. 2022 Apr;
22(1):352.
PMID: 35397492
Background: Invasive fungal diseases (IFD) remain a major complication of allogeneic hematopoietic stem cell transplantation (alloHSCT) and are associated with high mortality rates in patients receiving alloHSCT. Antifungal prophylaxis is...